Iron chelation in the treatment of neurodegenerative diseases

Journal of Trace Elements in Medicine and Biology

Volumn 38, Issue , 2016, Pages 81-92

  Dusek, Petr ^a,b   Schneider, Susanne A ^c   Aaseth, Jan ^d,e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d INNLANDET HOSPITAL TRUST   (Norway)

^e INLAND NORWAY UNIVERSITY OF APPLIED SCIENCES   (Norway)

Author keywords

Friedreich's ataxia; Iron chelation; Multiple sclerosis; NBIA; Parkinson's disease; Superficial siderosis

Indexed keywords

CLIOQUINOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ACERULOPLASMINEMIA; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; DEGENERATIVE DISEASE; DISEASE DURATION; DRUG EFFICACY; FRIEDREICH ATAXIA; HUMAN; IRON CHELATION; MITOCHONDRIAL PROTEIN ASSOCIATED NEURODEGENERATION; MULTIPLE SCLEROSIS; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDEROSIS; SUPERFICIAL SIDEROSIS; TREATMENT DURATION; NEURODEGENERATIVE DISEASES;

HUMANS; IRON CHELATING AGENTS; NEURODEGENERATIVE DISEASES;

EID: 84992036208     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2016.03.010     Document Type: Review

References (184)

1. [1] Dusek, P., Litwin, T., Czlonkowska, A., Wilson disease and other neurodegenerations with metal accumulations. Neurol. Clin. 33:1 (2015), 175–204.
2. [2] Ward, R.J., Zucca, F.A., Duyn, J.H., Crichton, R.R., Zecca, L., The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13:10 (2014), 1045–1060.
3. [3] Dusek, P., Jankovic, J., Le, W., Iron dysregulation in movement disorders. Neurobiol. Dis. 46:1 (2012), 1–18.
4. [4] Ward, R.J., Dexter, D.T., Crichton, R.R., Neurodegenerative diseases and therapeutic strategies using iron chelators. J. Trace Elem. Med. Biol. 31 (2015), 267–273.
5. [5] Schneider, S.A., Dusek, P., Hardy, J., Westenberger, A., Jankovic, J., Bhatia, K.P., Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr. Neuropharmacol. 11:1 (2013), 59–79.
6. [6] Koeppen, A.H., Michael, S.C., Li, D., Chen, Z., Cusack, M.J., Gibson, W.M., Petrocine, S.V., Qian, J., The pathology of superficial siderosis of the central nervous system. Acta Neuropathol. 116:4 (2008), 371–382.
7. [7] Schrag, M., McAuley, G., Pomakian, J., Jiffry, A., Tung, S., Mueller, C., Vinters, H.V., Haacke, E.M., Holshouser, B., Kido, D., Kirsch, W.M., Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol. 119:3 (2010), 291–302.
8. [8] Adams, C.W., Perivascular iron deposition and other vascular damage in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 51:2 (1988), 260–265.
9. [9] Lopes, K.O., Sparks, D.L., Streit, W.J., Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 56:10 (2008), 1048–1060.
10. [10] Andersen, H.H., Johnsen, K.B., Moos, T., Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell. Mol. Life Sci. 71:9 (2014), 1607–1622.
11. [11] Thomsen, M.S., Andersen, M.V., Christoffersen, P.R., Jensen, M.D., Lichota, J., Moos, T., Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons. Neurobiol. Dis. 81 (2015), 108–118.
12. [12] Harris, Z.L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R.T., Gitlin, J.D., Aceruloplasminemia molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. U. S. A. 92:7 (1995), 2539–2543.
13. [13] Curtis, A.R., Fey, C., Morris, C.M., Bindoff, L.A., Ince, P.G., Chinnery, P.F., Coulthard, A., Jackson, M.J., Jackson, A.P., McHale, D.P., Hay, D., Barker, W.A., Markham, A.F., Bates, D., Curtis, A., Burn, J., Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28:4 (2001), 350–354.
14. [14] Mendel, G.A., Studies on iron absorption. I. The relationships between the rate of erythropoiesis hypoxia and iron absorption. Blood 18 (1961), 727–736.
15. [15] Mastroberardino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylor, G., Cheng, D., Na, H.M., Gutekunst, C.A., Gearing, M., Trojanowski, J.Q., Anderson, M., Chu, C.T., Peng, J., Greenamyre, J.T., A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34:3 (2009), 417–431.
16. [16] Terman, A., Kurz, T., Lysosomal iron, iron chelation, and cell death. Antioxid. Redox Signal. 18:8 (2013), 888–898.
17. [17] Zhang, Y., Mikhael, M., Xu, D., Li, Y., Soe-Lin, S., Ning, B., Li, W., Nie, G., Zhao, Y., Ponka, P., Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid. Redox Signal. 13:7 (2010), 999–1009.
18. [18] Esterbauer, H., Schaur, R.J., Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 11:1 (1991), 81–128.
19. [19] Kaneko, K., Yoshida, K., Arima, K., Ohara, S., Miyajima, H., Kato, T., Ohta, M., Ikeda, S.I., Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J. Neuropathol. Exp. Neurol. 61:12 (2002), 1069–1077.
20. [20] Persson, T., Popescu, B.O., Cedazo-Minguez, A., Oxidative stress in alzheimer's disease: why did antioxidant therapy fail?. Oxid. Med. Cell. Longev., 2014, 2014, 427318.
21. [21] Lovell, M.A., Soman, S., Bradley, M.A., Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain. Mech. Ageing Dev. 132:8-9 (2011), 443–448.
22. [22] Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R., Milzani, A., Protein carbonylation in human diseases. Trends Mol. Med. 9:4 (2003), 169–176.
23. [23] Dalle-Donne, I., Rossi, R., Giustarini, D., Milzani, A., Colombo, R., Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 329:1-2 (2003), 23–38.
24. [24] Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K., Youdim, M.B., Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:2 (1989), 515–520.
25. [25] Zhang, X., Surguladze, N., Slagle-Webb, B., Cozzi, A., Connor, J.R., Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 54:8 (2006), 795–804.
26. [26] Uversky, V.N., Li, J., Fink, A.L., Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein: a possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276:47 (2001), 44284–44296.
27. [27] Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., Masliah, E., Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10:4 (1999), 717–721.
28. [28] Li, W.J., Jiang, H., Song, N., Xie, J.X., Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci. Bull. 26:3 (2010), 205–210.
29. [29] Bogdan, A.R., Miyazawa, M., Hashimoto, K., Tsuji, Y., Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci. 41:3 (2016), 274–286.
30. [30] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis an iron-dependent form of nonapoptotic cell death. Cell 149:5 (2012), 1060–1072.
31. [31] Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Ferroptosis, Tang D., process and function. Cell Death Differ. 23:3 (2016), 369–379.
32. [32] Castellani, R.J., Siedlak, S.L., Perry, G., Smith, M.A., Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100:2 (2000), 111–114.
33. [33] Jin, L., Wang, J., Zhao, L., Jin, H., Fei, G., Zhang, Y., Zeng, M., Zhong, C., Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134:Pt 1 (2011), 50–58.
34. [34] Schmalbrock, P., Prakash, R.S., Schirda, B., Janssen, A., Yang, G.K., Russell, M., Knopp, M.V., Boster, A., Nicholas, J.A., Racke, M., Pitt, D., Basal ganglia iron in patients with multiple sclerosis measured with 7T quantitative susceptibility mapping correlates with inhibitory control. AJNR Am. J. Neuroradiol., 2015.
35. [35] Khalil, M., Langkammer, C., Pichler, A., Pinter, D., Gattringer, T., Bachmaier, G., Ropele, S., Fuchs, S., Enzinger, C., Fazekas, F., Dynamics of brain iron levels in multiple sclerosis: a longitudinal 3T MRI study. Neurology 84:24 (2015), 2396–2402.
36. [36] Ghadery, C., Pirpamer, L., Hofer, E., Langkammer, C., Petrovic, K., Loitfelder, M., Schwingenschuh, P., Seiler, S., Duering, M., Jouvent, E., Schmidt, H., Fazekas, F., Mangin, J.F., Chabriat, H., Dichgans, M., Ropele, S., Schmidt, R., R2* mapping for brain iron: associations with cognition in normal aging. Neurobiol. Aging 36:2 (2015), 925–932.
37. [37] Penke, L., Valdes Hernandez, M.C., Maniega, S.M., Gow, A.J., Murray, C., Starr, J.M., Bastin, M.E., Deary, I.J., Wardlaw, J.M., Brain iron deposits are associated with general cognitive ability and cognitive aging. Neurobiol. Aging 33:3 (2012), 510–517 (e2).
38. [38] Li, W., Langkammer, C., Chou, Y.H., Petrovic, K., Schmidt, R., Song, A.W., Madden, D.J., Ropele, S., Liu, C., Association between increased magnetic susceptibility of deep gray matter nuclei and decreased motor function in healthy adults. Neuroimage 105 (2015), 45–52.
39. [39] Daugherty, A.M., Haacke, E.M., Raz, N., Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults. J. Neurosci. 35:17 (2015), 6731–6743.
40. [40] Daugherty, A.M., Raz, N., Accumulation of iron in the putamen predicts its shrinkage in healthy older adults: a multi-occasion longitudinal study. Neuroimage 128 (2016), 11–20.
41. [41] Miyajima, H., Aceruloplasminemia. Neuropathology 35:1 (2015), 83–90.
42. [42] Morita, H., Ikeda, S., Yamamoto, K., Morita, S., Yoshida, K., Nomoto, S., Kato, M., Yanagisawa, N., Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann. Neurol. 37:5 (1995), 646–656.
43. [43] Chen, Q., Chen, X.P., Zou, L., Zhou, D., Gong, Q.Y., Burgunder, J.M., Shang, H.F., High brain iron level in asymptomatic carriers of heterozygous ceruloplasmin gene mutations. Mov. Disord. 23:6 (2008), 916–917.
44. [44] Badat, M., Kaya, B., Telfer, P., Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia. Br. J. Haematol. 171:3 (2015), 430–432.
45. [45] Finkenstedt, A., Wolf, E., Hofner, E., Gasser, B.I., Bosch, S., Bakry, R., Creus, M., Kremser, C., Schocke, M., Theurl, M., Moser, P., Schranz, M., Bonn, G., Poewe, W., Vogel, W., Janecke, A.R., Zoller, H., Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J. Hepatol. 53:6 (2010), 1101–1107.
46. [46] Lindner, U., Schuppan, D., Schleithoff, L., Habeck, J.O., Grodde, T., Kirchhof, K., Stoelzel, U., Aceruloplasminaemia a family with a novel mutation and long-term therapy with deferasirox. Horm. Metab. Res. 47:4 (2015), 303–308.
47. [47] McNeill, A., Pandolfo, M., Kuhn, J., Shang, H., Miyajima, H., The neurological presentation of ceruloplasmin gene mutations. Eur. Neurol. 60:4 (2008), 200–205.
48. [48] Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., Gitlin, J.D., Use of desferrioxamine in the treatment of aceruloplasminemia. Ann. Neurol. 41:3 (1997), 404–407.
49. [49] Pan, P.L., Tang, H.H., Chen, Q., Song, W., Shang, H.F., Desferrioxamine treatment of aceruloplasminemia: long-term follow-up. Mov. Disord. 26:11 (2011), 2142–2144.
50. [50] Skidmore, F.M., Drago, V., Foster, P., Schmalfuss, I.M., Heilman, K.M., Streiff, R.R., Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J. Neurol. Neurosurg. Psychiatry 79:4 (2008), 467–470.
51. [51] Suzuki, Y., Yoshida, K., Aburakawa, Y., Kuroda, K., Kimura, T., Terada, T., Kono, S., Miyajima, H., Yahara, O., Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern. Med. 52:13 (2013), 1527–1530.
52. [52] Roberti Mdo, R., Borges Filho, H.M., Goncalves, C.H., Lima, F.L., Aceruloplasminemia a rare disease ? diagnosis and treatment of two cases. Rev. Bras. Hematol. Hemoter. 33:5 (2011), 389–392.
53. [53] Bethlehem, C., van Harten, B., Hoogendoorn, M., Central nervous system involvement in a rare genetic iron overload disorder. Neth. J. Med. 68:10 (2010), 316–318.
54. [54] Hida, A., Kowa, H., Iwata, A., Tanaka, M., Kwak, S., Tsuji, S., Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis. J. Neurol. Sci. 298:1–2 (2010), 136–139.
55. [55] Yonekawa, M., Okabe, T., Asamoto, Y., Ohta, M., A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur. Neurol. 42:3 (1999), 157–162.
56. [56] Loreal, O., Turlin, B., Pigeon, C., Moisan, A., Ropert, M., Morice, P., Gandon, Y., Jouanolle, A.M., Verin, M., Hider, R.C., Yoshida, K., Brissot, P., Aceruloplasminemia new clinical, pathophysiological and therapeutic insights. J. Hepatol. 36:6 (2002), 851–856.
57. [57] Haemers, I., Kono, S., Goldman, S., Gitlin, J.D., Pandolfo, M., Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia. J. Neurol. Neurosurg. Psychiatry 75:2 (2004), 334–337.
58. [58] Mariani, R., Arosio, C., Pelucchi, S., Grisoli, M., Piga, A., Trombini, P., Piperno, A., Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 53:5 (2004), 756–758.
59. [59] Bove, F., Fasano, A., Iron chelation therapy to prevent the manifestations of aceruloplasminemia. Neurology 85:12 (2015), 1085–1086.
60. [60] Vroegindeweij, L.H., van der Beek, E.H., Boon, A.J., Hoogendoorn, M., Kievit, J.A., Wilson, J.H., Langendonk, J.G., Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series. Diabet. Med. 32:8 (2015), 993–1000.
61. [61] Doyle, A., Rusli, F., Bhathal, P., Aceruloplasminaemia a rare but important cause of iron overload. BMJ Case Rep., 2015, 2015.
62. [62] Fasano, A., Colosimo, C., Miyajima, H., Tonali, P.A., Re, T.J., Bentivoglio, A.R., Aceruloplasminemia a novel mutation in a family with marked phenotypic variability. Mov. Disord. 23:5 (2008), 751–755.
63. [63] Rusticeanu, M., Zimmer, V., Schleithoff, L., Wonney, K., Viera, J., Zimmer, A., Hubschen, U., Bohle, R.M., Grunhage, F., Lammert, F., Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms. Clin. Genet. 85:3 (2014), 300–301.
64. [64] Tai, M., Matsuhashi, N., Ichii, O., Suzuki, T., Ejiri, Y., Kono, S., Terada, T., Miyajima, H., Harada, M., Case of presymptomatic aceruloplasminemia treated with deferasirox. Hepatol. Res. 44:12 (2014), 1253–1258.
65. [65] Zhou, B., Westaway, S.K., Levinson, B., Johnson, M.A., Gitschier, J., Hayflick, S.J., A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 28:4 (2001), 345–349.
66. [66] Meyer, E., Kurian, M.A., Hayflick, S.J., Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms. Annu. Rev. Genomics Hum. Genet. 16 (2015), 257–279.
67. [67] Dusek, P., Tovar Martinez, E.M., Madai, V.I., Jech, R., Sobesky, J., Paul, F., Niendorf, T., Wuerfel, J., Chneider, S.A., 7-Tesla magnetic resonance imaging for brain iron quantification in homozygous and heterozygous PANK2 mutation carriers. Mov. Disor. Clin. Pract. 1:4 (2014), 329–335.
68. [68] Dezortova, M., Herynek, V., Krssak, M., Kronerwetter, C., Trattnig, S., Hajek, M., Two forms of iron as an intrinsic contrast agent in the basal ganglia of PKAN patients. Contrast Media Mol. Imaging 7:6 (2012), 509–515.
69. [69] Woltjer, R.L., Reese, L.C., Richardson, B.E., Tran, H., Green, S., Pham, T., Chalupsky, M., Gabriel, I., Light, T., Sanford, L., Jeong, S.Y., Hamada, J., Schwanemann, L.K., Rogers, C., Gregory, A., Hogarth, P., Hayflick, S.J., Pallidal neuronal apolipoprotein E in pantothenate kinase-associated neurodegeneration recapitulates ischemic injury to the globus pallidus. Mol. Genet. Metab. 116:4 (2015), 289–297.
70. [70] Zorzi, G., Zibordi, F., Chiapparini, L., Bertini, E., Russo, L., Piga, A., Longo, F., Garavaglia, B., Aquino, D., Savoiardo, M., Solari, A., Nardocci, N., Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov. Disord. 26:9 (2011), 1756–1759.
71. [71] Cossu, G., Abbruzzese, G., Matta, G., Murgia, D., Melis, M., Ricchi, V., Galanello, R., Barella, S., Origa, R., Balocco, M., Pelosin, E., Marchese, R., Ruffinengo, U., Forni, G.L., Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up. Parkinsonism Relat. Disord. 20:6 (2014), 651–654.
72. [72] Abbruzzese, G., Cossu, G., Balocco, M., Marchese, R., Murgia, D., Melis, M., Galanello, R., Barella, S., Matta, G., Ruffinengo, U., Bonuccelli, U., Forni, G.L., A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 96:11 (2011), 1708–1711.
73. [73] Tomic, A., Petrovic, I., Svetel, M., Dobricic, V., Dragasevic Miskovic, N., Kostic, V.S., Pattern of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN) − Prospective study. Parkinsonism Relat. Disord. 21:5 (2015), 521–524.
74. [74] Pratini, N.R., Sweeters, N., Vichinsky, E., Neufeld, J.A., Treatment of classic pantothenate kinase-Associated neurodegeneration with deferiprone and intrathecal baclofen. Am. J. Phys. Med. Rehab., 2013.
75. [75] Gallyas, F., Kornyey, S., A further contribution to the knowledge of the Hallervorden-Spatz disease. Arch. Psychiatr. Nervenkr. 212:1 (1968), 33–45.
76. [76] Batla, A., Adams, M.E., Erro, R., Ganos, C., Balint, B., Mencacci, N.E., Bhatia, K.P., Cortical pencil lining in neuroferritinopathy: a diagnostic clue. Neurology 84:17 (2015), 1816–1818.
77. [77] Ohta, E., Takiyama, Y., MRI findings in neuroferritinopathy. Neurol. Res. Int., 2012, 2012, 197438.
78. [78] Keogh, M.J., Jonas, P., Coulthard, A., Chinnery, P.F., Burn, J., Neuroferritinopathy a new inborn error of iron metabolism. Neurogenetics 13:1 (2012), 93–96.
79. [79] Chinnery, P.F., Crompton, D.E., Birchall, D., Jackson, M.J., Coulthard, A., Lombes, A., Quinn, N., Wills, A., Fletcher, N., Mottershead, J.P., Cooper, P., Kellett, M., Bates, D., Burn, J., Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130:Pt 1 (2007), 110–119.
80. [80] Kubota, A., Hida, A., Ichikawa, Y., Momose, Y., Goto, J., Igeta, Y., Hashida, H., Yoshida, K., Ikeda, S., Kanazawa, I., Tsuji, S., A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov. Disord. 24:3 (2009), 441–445.
81. [81] Keogh, M.J., Morris, C.M., Chinnery, P.F., Neuroferritinopathy. Int. Rev. Neurobiol. 110 (2013), 91–123.
82. [82] Venco, P., Bonora, M., Giorgi, C., Papaleo, E., Iuso, A., Prokisch, H., Pinton, P., Tiranti, V., Mutations of C19orf12, coding for a transmembrane glycine zipper containing mitochondrial protein, cause mis-localization of the protein, inability to respond to oxidative stress and increased mitochondrial Ca(2)(+). Front. Genet., 6, 2015, 185.
83. [83] Lobel, U., Schweser, F., Nickel, M., Deistung, A., Grosse, R., Hagel, C., Fiehler, J., Schulz, A., Hartig, M., Reichenbach, J.R., Kohlschutter, A., Sedlacik, J., Brain iron quantification by MRI in mitochondrial membrane protein-associated neurodegeneration under iron-chelating therapy. Ann. Clin. Transl. Neurol. 1:12 (2014), 1041–1046.
84. [84] Forni, G.L., Balocco, M., Cremonesi, L., Abbruzzese, G., Parodi, R.C., Marchese, R., Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov. Disord. 23:6 (2008), 904–907.
85. [85] Kwiatkowski, A., Ryckewaert, G., Jissendi Tchofo, P., Moreau, C., Vuillaume, I., Chinnery, P.F., Destee, A., Defebvre, L., Devos, D., Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat. Disord. 18:1 (2012), 110–112.
86. [86] Koeppen, A.H., Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303:1-2 (2011), 1–12.
87. [87] Martelli, A., Puccio, H., Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front. Pharmacol., 5, 2014, 130.
88. [88] Anzovino, A., Lane, D.J., Huang, M.L., Richardson, D.R., Fixing frataxin: ‘ironing out’ the metabolic defect in Friedreich's ataxia. Br. J. Pharmacol. 171:8 (2014), 2174–2190.
89. [89] Kolnagou, A., Kontoghiorghe, C.N., Kontoghiorghes, G.J., Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J. Methodol. 4:4 (2014), 197–218.
90. [90] Pandolfo, M., Hausmann, L., Deferiprone for the treatment of Friedreich's ataxia. J. Neurochem. 126:Suppl 1 (2013), 142–146.
91. [91] Marmolino, D., Friedreich's ataxia: past, present and future. Brain Res. Rev. 67:1-2 (2011), 311–330.
92. [92] Igoillo-Esteve, M., Gurgul-Convey, E., Hu, A., Romagueira Bichara Dos Santos, L., Abdulkarim, B., Chintawar, S., Marselli, L., Marchetti, P., Jonas, J.C., Eizirik, D.L., Pandolfo, M., Cnop, M., Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia. Hum. Mol. Genet. 24:8 (2015), 2274–2286.
93. [93] Navarro, J.A., Botella, J.A., Metzendorf, C., Lind, M.I., Schneuwly, S., Mitoferrin modulates iron toxicity in a Drosophila model of Friedreich's ataxia. Free Radical Biol. Med. 85 (2015), 71–82.
94. [94] Koeppen, A.H., Mazurkiewicz, J.E., Friedreich ataxia: neuropathology revised. J. Neuropathol. Exp. Neurol. 72:2 (2013), 78–90.
95. [95] Michael, S., Petrocine, S.V., Qian, J., Lamarche, J.B., Knutson, M.D., Garrick, M.D., Koeppen, A.H., Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 5:4 (2006), 257–267.
96. [96] Koeppen, A.H., Ramirez, R.L., Becker, A.B., Bjork, S.T., Levi, S., Santambrogio, P., Parsons, P.J., Kruger, P.C., Yang, K.X., Feustel, P.J., Mazurkiewicz, J.E., The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One, 10(3), 2015, e0116396.
97. [97] Ramirez, R.L., Qian, J., Santambrogio, P., Levi, S., Koeppen, A.H., Relation of cytosolic iron excess to cardiomyopathy of Friedreich's ataxia. Am. J. Cardiol. 110:12 (2012), 1820–1827.
98. [98] Bonilha da Silva, C., Bergo, F.P., D'Abreu, A., Cendes, F., Lopes-Cendes, I., Franca, M.C. Jr., Dentate nuclei T2 relaxometry is a reliable neuroimaging marker in Friedreich's ataxia. Eur. J. Neurol. 21:8 (2014), 1131–1136.
99. [99] Solbach, K., Kraff, O., Minnerop, M., Beck, A., Schols, L., Gizewski, E.R., Ladd, M.E., Timmann, D., Cerebellar pathology in Friedreich's ataxia: atrophied dentate nuclei with normal iron content. Neuroimage Clin. 6 (2014), 93–99.
100. [100] Koeppen, A.H., Kuntzsch, E.C., Bjork, S.T., Ramirez, R.L., Mazurkiewicz, J.E., Feustel, P.J., Friedreich ataxia: metal dysmetabolism in dorsal root ganglia. Acta Neuropathol. Commun., 1(1), 2013, 26.
101. [101] Koeppen, A.H., Ramirez, R.L., Yu, D., Collins, S.E., Qian, J., Parsons, P.J., Yang, K.X., Chen, Z., Mazurkiewicz, J.E., Feustel, P.J., Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. Cerebellum, 2012.
102. [102] Boddaert, N., Le Quan Sang, K.H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.C., Munnich, A., Cabantchik, Z.I., Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110:1 (2007), 401–408.
103. [103] Velasco-Sanchez, D., Aracil, A., Montero, R., Mas, A., Jimenez, L., O'Callaghan, M., Tondo, M., Capdevila, A., Blanch, J., Artuch, R., Pineda, M., Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10:1 (2011), 1–8.
104. [104] Pandolfo, M., Arpa, J., Delatycki, M.B., Le Quan Sang, K.H., Mariotti, C., Munnich, A., Sanz-Gallego, I., Tai, G., Tarnopolsky, M.A., Taroni, F., Spino, M., Tricta, F., Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76:4 (2014), 509–521.
105. [105] Arpa, J., Sanz-Gallego, I., Rodriguez-de-Rivera, F.J., Dominguez-Melcon, F.J., Prefasi, D., Oliva-Navarro, J., Moreno-Yanguela, M., Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia—open-label trial. Acta Neurol. Scand. 129:1 (2014), 32–40.
106. [106] River, Y., Honigman, S., Gomori, J.M., Reches, A., Superficial hemosiderosis of the central nervous system. Mov. Disord. 9:5 (1994), 559–562.
107. [107] Schirinzi, T., Sancesario, G., Anemona, L., Pisani, A., Sancesario, G., CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiprone–a case report. Neurol. Sci. 35:7 (2014), 1151–1152.
108. [108] Levy, M., Turtzo, C., Llinas, R.H., Superficial siderosis: a case report and review of the literature. Nat. Clin. Pract. Neurol. 3:1 (2007), 54–58 (quiz 9).
109. [109] Charidimou, A., Ni, J., Martinez-Ramirez, S., Vashkevich, A., Ayres, A., Rosand, J., Gurol, E.M., Greenberg, S.M., Viswanathan, A., Cortical superficial siderosis in memory clinic patients: further evidence for underlying cerebral amyloid angiopathy. Cerebrovasc. Dis. 41:3–4 (2016), 156–162.
110. [110] Na, H.K., Park, J.H., Kim, J.H., Kim, H.J., Kim, S.T., Werring, D.J., Seo, S.W., Na, D.L., Cortical superficial siderosis: a marker of vascular amyloid in patients with cognitive impairment. Neurology 84:8 (2015), 849–855.
111. [111] Koeppen, A.H., Dentinger, M.P., Brain hemosiderin and superficial siderosis of the central nervous system. J. Neuropathol. Exp. Neurol. 47:3 (1988), 249–270.
112. [112] Parnes, S.M., Weaver, S.A., Superficial siderosis of the central nervous system: a neglected cause of sensorineural hearing loss. Otolaryngol. Head Neck Surg. 107:1 (1992), 69–77.
113. [113] Levy, M., Llinas, R.H., Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis. AJNR Am. J. Neuroradiol. 32:1 (2011), E1–2.
114. [114] Levy, M., Llinas, R.H., Update on a patient with superficial siderosis on deferiprone. AJNR Am. J. Neuroradiol. 33:6 (2012), E99–100.
115. [115] Cummins, G., Crundwell, G., Baguley, D., Lennox, G., Treatment of superficial siderosis with iron chelation therapy. BMJ Case Rep., 2013, 2013.
116. [116] Huprikar, N., Gossweiler, M., Callaghan, M., Bunge, P., Agranulocytosis with deferiprone treatment of superficial siderosis. BMJ Case Rep., 2013, 2013.
117. [117] Levy, M., Llinas, R., Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke 43:1 (2012), 120–124.
118. [118] Belaidi, A.A., Bush, A.I., Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J. Neurochem., 2015.
119. [119] Dusek, P., Roos, P.M., Litwin, T., Schneider, S.A., Flaten, T.P., Aaseth, J., The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases. J. Trace Elem. Med. Biol. 31 (2015), 193–203.
120. [120] Murakami, Y., Kakeda, S., Watanabe, K., Ueda, I., Ogasawara, A., Moriya, J., Ide, S., Futatsuya, K., Sato, T., Okada, K., Uozumi, T., Tsuji, S., Liu, T., Wang, Y., Korogi, Y., Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. AJNR Am. J. Neuroradiol. 36:6 (2015), 1102–1108.
121. [121] He, N., Ling, H., Ding, B., Huang, J., Zhang, Y., Zhang, Z., Liu, C., Chen, K., Yan, F., Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum. Brain Mapp. 36:11 (2015), 4407–4420.
122. [122] Du, G., Liu, T., Lewis, M.M., Kong, L., Wang, Y., Connor, J., Mailman, R.B., Huang, X., Quantitative susceptibility mapping of the midbrain in Parkinson's disease. Mov. Disord. 31:3 (2016), 317–324.
123. [123] Barbosa, J.H., Santos, A.C., Tumas, V., Liu, M., Zheng, W., Haacke, E.M., Salmon, C.E., Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn. Reson. Imaging 33:5 (2015), 559–565.
124. [124] Lotfipour, A.K., Wharton, S., Schwarz, S.T., Gontu, V., Schafer, A., Peters, A.M., Bowtell, R.W., Auer, D.P., Gowland, P.A., Bajaj, N.P., High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J. Magn. Reson. Imaging 35:1 (2012), 48–55.
125. [125] Zucca, F.A., Segura-Aguilar, J., Ferrari, E., Munoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., Zecca, L., Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog. Neurobiol., 2015.
126. [126] Zhang, W., Phillips, K., Wielgus, A.R., Liu, J., Albertini, A., Zucca, F.A., Faust, R., Qian, S.Y., Miller, D.S., Chignell, C.F., Wilson, B., Jackson-Lewis, V., Przedborski, S., Joset, D., Loike, J., Hong, J.S., Sulzer, D., Zecca, L., Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 19:1 (2011), 63–72.
127. [127] Morris, C.M., Edwardson, J.A., Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3:4 (1994), 277–282.
128. [128] Li, X.P., Xie, W.J., Zhang, Z., Kansara, S., Jankovic, J., Le, W.D., A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals 20:4 (2012), 223–236.
129. [129] Friedlich, A.L., Tanzi, R.E., Rogers, J.T., The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 12:3 (2007), 222–223.
130. [130] Febbraro, F., Giorgi, M., Caldarola, S., Loreni, F., Romero-Ramos, M., alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport 23:9 (2012), 576–580.
131. [131] Davies, P., Moualla, D., Brown, D.R., Alpha-synuclein is a cellular ferrireductase. PLoS One, 6(1), 2011, e15814.
132. [132] Sian-Hulsmann, J., Mandel, S., Youdim, M.B., Riederer, P., The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 118:6 (2011), 939–957.
133. [133] Weinreb, O., Mandel, S., Youdim, M.B., Amit, T., Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radical Biol. Med. 62 (2013), 52–64.
134. [134] Devos, D., Moreau, C., Devedjian, J.C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garcon, G., Rouaix, N., Duhamel, A., Jissendi, P., Dujardin, K., Auger, F., Ravasi, L., Hopes, L., Grolez, G., Firdaus, W., Sablonniere, B., Strubi-Vuillaume, I., Zahr, N., Destee, A., Corvol, J.C., Poltl, D., Leist, M., Rose, C., Defebvre, L., Marchetti, P., Cabantchik, Z.I., Bordet, R., Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21:2 (2014), 195–210.
135. [135] Grolez, G., Moreau, C., Sablonniere, B., Garcon, G., Devedjian, J.C., Meguig, S., Gele, P., Delmaire, C., Bordet, R., Defebvre, L., Cabantchik, I.Z., Devos, D., Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurol., 15, 2015, 74.
136. [136] Peters, D.G., Connor, J.R., Meadowcroft, M.D., The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: two sides of the same coin. Neurobiol. Dis. 81 (2015), 49–65.
137. [137] Schrag, M., Mueller, C., Oyoyo, U., Smith, M.A., Kirsch, W.M., Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis: some insight on the influence of citation bias on scientific opinion. Prog. Neurobiol. 94:3 (2011), 296–306.
138. [138] Meadowcroft, M.D., Peters, D.G., Dewal, R.P., Connor, J.R., Yang, Q.X., The effect of iron in MRI and transverse relaxation of amyloid-beta plaques in Alzheimer's disease. NMR Biomed. 28:3 (2015), 297–305.
139. [139] Zeineh, M.M., Chen, Y., Kitzler, H.H., Hammond, R., Vogel, H., Rutt, B.K., Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol. Aging 36:9 (2015), 2483–2500.
140. [140] Connor, J.R., Menzies, S.L., St Martin, S.M., Mufson, E.J., A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31:1 (1992), 75–83.
141. [141] Schrag, M., Crofton, A., Zabel, M., Jiffry, A., Kirsch, D., Dickson, A., Mao, X.W., Vinters, H.V., Domaille, D.W., Chang, C.J., Kirsch, W., Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease. J. Alzheimers Dis. 24:1 (2011), 137–149.
142. [142] Kuiper, M.A., Mulder, C., van Kamp, G.J., Scheltens, P., Wolters, E.C., Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J. Neural Transm. 7:2 (1994), 109–114.
143. [143] Ayton, S., Faux, N.G., Bush, A.I., Alzheimer's Disease Neuroimaging I. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat. Commun., 6, 2015, 6760.
144. [144] Everett, J., Cespedes, E., Shelford, L.R., Exley, C., Collingwood, J.F., Dobson, J., van der Laan, G., Jenkins, C.A., Arenholz, E., Telling, N.D., Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer's disease peptide beta-amyloid. Inorg. Chem. 53:6 (2014), 2803–2809.
145. [145] Everett, J., Cespedes, E., Shelford, L.R., Exley, C., Collingwood, J.F., Dobson, J., van der Laan, G., Jenkins, C.A., Arenholz, E., Telling, N.D., Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide beta-amyloid (1–42). J. R. Soc. Interface, 11(95), 2014, 20140165.
146. [146] Crapper McLachlan, D.R., Dalton, A.J., Kruck, T.P., Bell, M.Y., Smith, W.L., Kalow, W., Andrews, D.F., Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:8753 (1991), 1304–1308.
147. [147] Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R.E., Masters, C.L., Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease—a pilot phase 2 clinical trial. Arch. Neurol. 60:12 (2003), 1685–1691.
148. [148] Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C.L., Targum, S., Bush, A.I., Murdoch, R., Wilson, J., Ritchie, C.W., Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7:9 (2008), 779–786.
149. [149] Faux, N.G., Ritchie, C.W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., Ingelsson, M., Masters, C.L., Tanzi, R.E., Cummings, J.L., Herd, C.M., Bush, A.I., PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J. Alzheimers Dis. 20:2 (2010), 509–516.
150. [150] Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Bruck, W., Lassmann, H., Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol., 2013.
151. [151] Haider, L., Inflammation Iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis. Oxid. Med. Cell. Longev., 2015, 2015, 725370.
152. [152] Stephenson, E., Nathoo, N., Mahjoub, Y., Dunn, J.F., Yong, V.W., Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat. Rev. Neurol. 10:8 (2014), 459–468.
153. [153] Williams, R., Buchheit, C.L., Berman, N.E., LeVine, S.M., Pathogenic implications of iron accumulation in multiple sclerosis. J. Neurochem. 120:1 (2012), 7–25.
154. [154] Stankiewicz, J.M., Neema, M., Ceccarelli, A., Iron and multiple sclerosis. Neurobiol. Aging 35:Suppl. 2 (2014), S51–8.
155. [155] Stuber, C., Pitt, D., Wang, Y., Iron in multiple sclerosis and its noninvasive imaging with quantitative susceptibility mapping. Int. J. Mol. Sci., 17(1), 2015.
156. [156] Blazejewska, A.I., Al-Radaideh, A.M., Wharton, S., Lim, S.Y., Bowtell, R.W., Constantinescu, C.S., Gowland, P.A., Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: a 7 Tesla MRI study. J. Magn. Reson. Imaging 41:4 (2015), 1065–1070.
157. [157] Al-Radaideh, A.M., Wharton, S.J., Lim, S.Y., Tench, C.R., Morgan, P.S., Bowtell, R.W., Constantinescu, C.S., Gowland, P.A., Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome. Mult. Scler. 19:7 (2013), 896–903.
158. [158] Modica, C.M., Zivadinov, R., Dwyer, M.G., Bergsland, N., Weeks, A.R., Benedict, R.H., Iron and volume in the deep gray matter: association with cognitive impairment in multiple sclerosis. AJNR Am. J. Neuroradiol. 36:1 (2015), 57–62.
159. [159] Ropele, S., Kilsdonk, I.D., Wattjes, M.P., Langkammer, C., de Graaf, W.L., Frederiksen, J.L., Larsson, H.B., Yiannakas, M., Wheeler-Kingshott, C.A., Enzinger, C., Khalil, M., Rocca, M.A., Sprenger, T., Amann, M., Kappos, L., Filippi, M., Rovira, A., Ciccarelli, O., Barkhof, F., Fazekas, F., Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Mult. Scler. 20:13 (2014), 1692–1698.
160. [160] Zhang, Y., Gauthier, S.A., Gupta, A., Comunale, J., Chia-Yi Chiang, G., Zhou, D., Chen, W., Giambrone, A.E., Zhu, W., Wang, Y., Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM). J. Magn. Reson. Imaging, 2016.
161. [161] Chen, W., Gauthier, S.A., Gupta, A., Comunale, J., Liu, T., Wang, S., Pei, M., Pitt, D., Wang, Y., Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 271:1 (2014), 183–192.
162. [162] Bozin, I., Ge, Y., Kuchling, J., Dusek, P., Chawla, S., Harms, L., Ruprecht, K., Niendorf, T., Paul, F., Kister, I., Sinnecker, T., Wuerfel, J., Magnetic resonance phase alterations in multiple sclerosis patients with short and long disease duration. PLoS One, 10(7), 2015, e0128386.
163. [163] Wisnieff, C., Ramanan, S., Olesik, J., Gauthier, S., Wang, Y., Pitt, D., Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: interpreting positive susceptibility and the presence of iron. Magn. Reson. Med. 74:2 (2015), 564–570.
164. [164] Haider, L., Simeonidou, C., Steinberger, G., Hametner, S., Grigoriadis, N., Deretzi, G., Kovacs, G.G., Kutzelnigg, A., Lassmann, H., Frischer, J.M., Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry 85:12 (2014), 1386–1395.
165. [165] Connor, J.R., Menzies, S.L., St Martin, S.M., Mufson, E.J., Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27:4 (1990), 595–611.
166. [166] Todorich, B., Pasquini, J.M., Garcia, C.I., Paez, P.M., Connor, J.R., Oligodendrocytes and myelination: the role of iron. Glia 57:5 (2009), 467–478.
167. [167] Mehta, V., Pei, W., Yang, G., Li, S., Swamy, E., Boster, A., Schmalbrock, P., Pitt, D., Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One, 8(3), 2013, e57573.
168. [168] Heidari, M., Johnstone, D.M., Bassett, B., Graham, R.M., Chua, A.C., House, M.J., Collingwood, J.F., Bettencourt, C., Houlden, H., Ryten, M., Olynyk, J.K., Trinder, D., Milward, E.A., Brain iron accumulation affects myelin-related molecular systems implicated in a rare neurogenetic disease family with neuropsychiatric features. Mol. Psychiatry, 2016.
169. [169] Weigel, K.J., Lynch, S.G., LeVine, S.M., Iron chelation and multiple sclerosis. ASN Neuro, 6(1), 2014, e00136.
170. [170] Choi, B.Y., Jang, B.G., Kim, J.H., Seo, J.N., Wu, G., Sohn, M., Chung, T.N., Suh, S.W., Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. Neurobiol. Dis. 54 (2013), 382–391.
171. [171] Zanella, S.G., Roberti di Sarsina, P., Personalization of multiple sclerosis treatments: using the chelation therapy approach. Explore (NY) 9:4 (2013), 244–248.
172. [172] Norstrand, I.F., Craelius, W., A trial of deferoxamine (desferal) in the treatment of multiple-sclerosis − a pilot-study. Clin. Trials J. 26:6 (1989), 365–369.
173. [173] Lynch, S.G., Peters, K., LeVine, S.M., Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. Mult. Scler. 2:3 (1996), 157–160.
174. [174] Lynch, S.G., Fonseca, T., LeVine, S.M., A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell. Mol. Biol. (Noisy-le-grand) 46:4 (2000), 865–869.
175. [175] Cumings, J.N., Trace metals in the brain and in Wilson's disease. J. Clin. Pathol. 21:1 (1968), 1–7.
176. [176] Mikol, J., Vital, C., Wassef, M., Chappuis, P., Poupon, J., Lecharpentier, M., Woimant, F., Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases. Acta Neuropathol. 110:5 (2005), 451–458.
177. [177] Walshe, J.M., Gibbs, K.R., Brain copper in Wilson's disease. Lancet, 2(8566), 1987, 1030.
178. [178] Walshe, J.M., Yealland, M., Chelation treatment of neurological Wilson's disease. Q. J. Med. 86:3 (1993), 197–204.
179. [179] Kakhlon, O., Breuer, W., Munnich, A., Cabantchik, Z.I., Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can. J. Physiol. Pharmacol. 88:3 (2010), 187–196.
180. [180] Aaseth, J., Skaug, M.A., Cao, Y., Andersen, O., Chelation in metal intoxication–Principles and paradigms. J. Trace Elem. Med. Biol. 31 (2015), 260–266.
181. [181] Mourad, F.H., Hoffbrand, A.V., Sheikh-Taha, M., Koussa, S., Khoriaty, A.I., Taher, A., Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. 121:1 (2003), 187–189.
182. [182] Totadri, S., Bansal, D., Bhatia, P., Attri, S.V., Trehan, A., Marwaha, R.K., The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study. Pediatr. Blood Cancer 62:9 (2015), 1592–1596.
183. [183] Cabantchik, Z.I., Munnich, A., Youdim, M.B., Devos, D., Regional siderosis: a new challenge for iron chelation therapy. Front. Pharmacol., 4, 2013, 167.
184. [184] Kalman, B., Lautenschlaeger, R., Kohlmayer, F., Buchner, B., Kmiec, T., Klopstock, T., Kuhn, K.A., An international registry for neurodegeneration with brain iron accumulation. Orphanet J. Rare Dis., 7, 2012, 66.